Syngene International Management
Management criteria checks 2/4
Syngene International's CEO is Jonathan Hunt, appointed in Jan 2016, has a tenure of 8.83 years. total yearly compensation is ₹285.33M, comprised of 50% salary and 50% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth ₹215.40M. The average tenure of the management team and the board of directors is 6.1 years and 5.3 years respectively.
Key information
Jonathan Hunt
Chief executive officer
₹285.3m
Total compensation
| CEO salary percentage | 50.0% |
| CEO tenure | 8.8yrs |
| CEO ownership | 0.06% |
| Management average tenure | 6.1yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Why Syngene International's (NSE:SYNGENE) Shaky Earnings Are Just The Beginning Of Its Problems
Oct 31
Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing
Jul 16These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely
Mar 28Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?
Feb 14Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)
Jan 19Is Syngene International (NSE:SYNGENE) A Risky Investment?
Nov 19Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?
Nov 01Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly
Aug 07These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely
Apr 28Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching
Apr 06Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?
Jan 04Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet
Dec 08Is Syngene International (NSE:SYNGENE) Using Too Much Debt?
Aug 28Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate
Aug 10These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well
May 10Does Syngene International (NSE:SYNGENE) Have A Healthy Balance Sheet?
Feb 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹5b |
| Jun 30 2024 | n/a | n/a | ₹5b |
| Mar 31 2024 | ₹285m | ₹143m | ₹5b |
| Dec 31 2023 | n/a | n/a | ₹5b |
| Sep 30 2023 | n/a | n/a | ₹5b |
| Jun 30 2023 | n/a | n/a | ₹5b |
| Mar 31 2023 | ₹85m | ₹85m | ₹5b |
| Dec 31 2022 | n/a | n/a | ₹4b |
| Sep 30 2022 | n/a | n/a | ₹4b |
| Jun 30 2022 | n/a | n/a | ₹4b |
| Mar 31 2022 | ₹76m | ₹76m | ₹4b |
| Dec 31 2021 | n/a | n/a | ₹4b |
| Sep 30 2021 | n/a | n/a | ₹4b |
| Jun 30 2021 | n/a | n/a | ₹4b |
| Mar 31 2021 | ₹65m | ₹65m | ₹4b |
| Dec 31 2020 | n/a | n/a | ₹4b |
| Sep 30 2020 | n/a | n/a | ₹4b |
| Jun 30 2020 | n/a | n/a | ₹4b |
| Mar 31 2020 | ₹66m | ₹66m | ₹4b |
| Dec 31 2019 | n/a | n/a | ₹4b |
| Sep 30 2019 | n/a | n/a | ₹4b |
| Jun 30 2019 | n/a | n/a | ₹3b |
| Mar 31 2019 | ₹90m | ₹47m | ₹3b |
| Dec 31 2018 | n/a | n/a | ₹3b |
| Sep 30 2018 | n/a | n/a | ₹3b |
| Jun 30 2018 | n/a | n/a | ₹3b |
| Mar 31 2018 | ₹94m | ₹47m | ₹3b |
Compensation vs Market: Jonathan's total compensation ($USD3.38M) is above average for companies of similar size in the Indian market ($USD590.37K).
Compensation vs Earnings: Jonathan's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Jonathan Hunt (55 yo)
8.8yrs
Tenure
₹285,330,000
Compensation
Mr. Jonathan Brittan Hunt serves as the Managing Director of Syngene International Limited since April 1, 2020. He has been the Chief Executive Officer of Syngene International Ltd. since January 2016 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Executive Director | 8.8yrs | ₹285.33m | 0.062% ₹ 215.4m | |
| CFO & Executive Director | 4.9yrs | ₹34.14m | 0.030% ₹ 103.8m | |
| Chief Scientific Officer | less than a year | no data | 0% ₹ 0 | |
| Head of Investor Relations | no data | no data | 0.0016% ₹ 5.4m | |
| Head of Legal | 5.3yrs | ₹4.72m | 0.0024% ₹ 8.3m | |
| Head of Corporate Communications | no data | no data | no data | |
| Chief Human Resources Officer | 1.9yrs | no data | no data | |
| Head of Pharmaceutical & Biopharmaceutical Development | no data | ₹10.80m | no data | |
| Head of Formulations Development | no data | ₹5.50m | 0.025% ₹ 86.9m | |
| Head of IT | 8.8yrs | no data | 0.00038% ₹ 1.3m | |
| Head of Clinical Development & Stability Studies | 8.8yrs | no data | 0.0060% ₹ 20.9m | |
| Head of EHSS | 6.8yrs | no data | 0.0093% ₹ 32.6m |
6.1yrs
Average Tenure
Experienced Management: SYNGENE's management team is seasoned and experienced (6.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Executive Director | 7.5yrs | ₹285.33m | 0.062% ₹ 215.4m | |
| CFO & Executive Director | less than a year | ₹34.14m | 0.030% ₹ 103.8m | |
| Non-Executive Director | 24.3yrs | ₹8.28m | 0.0022% ₹ 7.6m | |
| Non-Executive Chairperson | no data | ₹9.43m | 0.0055% ₹ 19.1m | |
| Lead Independent Director | 7.3yrs | ₹8.62m | no data | |
| Independent Director | 7.7yrs | ₹7.46m | 0.012% ₹ 43.5m | |
| Additional Independent Director | less than a year | no data | no data | |
| Independent Non Executive Director | 3.4yrs | ₹6.47m | no data | |
| Independent Director | less than a year | no data | no data | |
| Additional Independent Director | 5.3yrs | ₹8.46m | no data |
5.3yrs
Average Tenure
61yo
Average Age
Experienced Board: SYNGENE's board of directors are considered experienced (5.3 years average tenure).